Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allogeneic bone marrow transplantation in leukemia.

A Gratwohl1, G Gahrton

  • 1Department of Internal Medicine, Kantonspital Basel, Switzerland.

Acta Oncologica (Stockholm, Sweden)
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017
Same author

Latin America: the next region for haematopoietic transplant progress.

Bone marrow transplantation·2017
Same author

Alloreactivity: the Janus-face of hematopoietic stem cell transplantation.

Leukemia·2017
Same author

Latin America: the next region for haematopoietic transplant progress.

Bone marrow transplantation·2017
Same author

The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis.

Bone marrow transplantation·2016
Same author

Allogeneic Bone Marrow Transplantation in Chronic Lymphocytic Leukemia: 17 Cases. Report of the EBMT.

Leukemia & lymphoma·2016

Bone marrow transplantation offers hope for hematological malignancies. Optimal outcomes for leukemia-free survival are achieved when transplants are performed during early disease phases, with 50% of patients remaining well at 8 years.

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Medicine

Background:

  • Hematological malignancies pose significant treatment challenges.
  • Bone marrow transplantation (BMT) is a critical therapeutic option.
  • European BMT registry data provides valuable insights into treatment outcomes.

Purpose of the Study:

  • To analyze European experience with bone marrow transplantation for hematological malignancies.
  • To identify factors influencing leukemia-free survival post-transplantation.
  • To report on outcomes from a large cohort of BMT procedures.

Main Methods:

  • Retrospective analysis of 2224 bone marrow transplants reported to the European registry from 1979 to December 1986.
  • Evaluation of leukemia-free survival rates based on disease phase, patient demographics, and prophylactic measures.

Related Experiment Videos

  • Statistical assessment of factors impacting long-term patient outcomes.

    • Main Results:

    • Leukemia-free survival is significantly higher when BMT is performed in the first complete remission of acute leukemia or the first chronic phase of chronic myeloid leukemia.
    • Approximately 50% of patients are alive and well 8 years post-transplantation under optimal conditions.
    • Age, donor-recipient sex combination, and the use of cyclosporine for graft-versus-host disease prevention are identified as key influencing factors.

    Conclusions:

    • Early intervention in leukemia treatment through BMT in specific disease phases maximizes long-term survival.
    • Cyclosporine prophylaxis is crucial for improving graft-versus-host disease management and overall survival.
    • This European experience highlights the importance of timing and specific patient/donor factors in optimizing BMT success for hematological cancers.